The complaint alleges that Elan failed to disclose and misrepresented material adverse facts in connection with Tysabri including serious immune-system side effects and that the information was concealed in order to fast track Tysabri for FDA approval.
In any event, notwithstanding that Merck continues to contend that it will try every single case, legal analysts say, state courts will never be able to handle the trials for the lawsuits already filed, much less the additional cases still being filed on a regular basis.
"At some point courts are going to be clogged with these cases and judges will start to put pressure on Merck and the plaintiffs to settle these cases," according to John Leubsdorf, professor of law at Rutgers Law School, on CNN Moneyline on April 26, 2006.
"The only scenario in which they won't settle," he says, "is if they win so much that all the plaintiffs go away."
But legal experts say, that is definitely not going to happen.
Information for injured parties can be found at Lawyers and Settlements.com
http://www.lawyersandsettlements.com/articles/merck_vioxx_lawsuit.html
Evelyn Pringle
evelyn.pringle@sbcglobal.net
1 | 2 | 3 | 4 | 5 | 6 | 7
Evelyn Pringle is a columnist for OpEd News and investigative journalist focused on exposing corruption in government and corporate America.
Comments
The time limit for entering new comments on this article has expired.
This limit can be removed. Our paid membership program is designed to give
you many benefits, such as removing this time limit. To learn more, please click here.